RVBA-KENVU

Kenvue Inc. — in detail

Full extracted data, every event in the company's history we've captured, and (soon) external news. The full ratios diagnostic with peer benchmarks lives at /ratios.

Reference sources (1/5)

Source documents
Recent disclosure
Multi-year metrics
Targets
Certifications

External news

No ESG-relevant news ingested yet for this company. Run python -m pipeline.news_gdelt to backfill. Sourced from GDELT 2.0 (3-month trailing window).

Data by year· every metric + key events per year

Each year shows the firm's reported metrics on the left and the most material events on the right. Up to 10 events per year; the full event log is one click further.

2024

sustainability report ↗

P&L highlights (USD)

Headcount (FTE)	22,000people
Revenue	15.5B
Cost of revenue	(6.5B)
Gross profit	9B
Total operating expenses	(6.3B)

Balance sheet highlights (USD)

Property, plant & equipment	1.8B
Right-of-use (leased) assets	222M
Total assets	25.6B
Total debt	8.6B
Cash & equivalents	1.1B

Market & shares

Market cap (FY-end)

34.8B

Events 2024· 3

2024 Multi-Year Restructuring Initiative (Our Vue Forward)

On May 6, 2024 the Board approved a multi-year restructuring initiative targeting ~$550M in pre-tax restructuring expenses and other charges and ~$350M of annualized pre-tax gross cost savings by fiscal year 2026. Includes global workforce reductions, management changes, and centralized shared-service functions in lower-cost locations. Kenvue incurred $221M of restructuring-related charges in fiscal 2024.

▾ expand

Dr.Ci:Labo skin health business $488M impairment

In Q2 2024 Kenvue recorded a non-cash $488M impairment ($337M after tax) on intangible assets and PP&E of the Dr.Ci:Labo skin health business, driven by shifts in consumer sentiment in China and changing shopping patterns. The trigger was a senior leadership change and revised internal forecasts.

▾ expand

Healthy Lives Mission with nine ESG priority areas

Kenvue's Healthy Lives Mission is its ESG strategy, supported by three pillars (Healthy People, Healthy Planet, Healthy Practice) and nine priority areas with public goals and commitments. Details are reported separately in the Healthy Lives Mission Report and an inaugural TCFD Report, not in this 10-K.

▾ expand

2023

P&L highlights (USD)

Revenue	15.4B
Cost of revenue	(6.8B)
Gross profit	8.6B
Total operating expenses	(6.1B)

Balance sheet highlights (USD)

Property, plant & equipment	2B
Right-of-use (leased) assets	139M
Total assets	27.9B
Total debt	8.3B
Cash & equivalents	1.4B

Events 2023· 2

Talc-based Johnson's Baby Powder discontinued globally in 2023

Kenvue announced in August 2022 the transition to an all cornstarch-based baby powder portfolio. Talc-based Johnson's Baby Powder was discontinued globally in 2023 (previously discontinued in U.S./Canada in 2020). J&J retained the U.S./Canada Talc-Related Liabilities under the Separation Agreement.

▾ expand

Separation from Johnson & Johnson completed

In August 2023, J&J completed the Exchange Offer, transferring 80.1% of Kenvue common stock to its shareholders, completing Kenvue's separation from J&J and transition to a fully independent public company. In May 2024, J&J completed the Debt for Equity Exchange, after which J&J no longer owned any Kenvue shares. The Separation results in new and increased reporting demands and disclosures previously embedded in J&J's filings.

▾ expand

2022

P&L highlights (USD)

Revenue	15B
Cost of revenue	(6.7B)
Gross profit	8.3B
Total operating expenses	(5.6B)